Hormone Replacement Therapy and Breast Cancer Risk

JAMA: The Journal of the American Medical Association

Volumn 275, Issue 15, 1996, Pages 1159-

  Campagnoli, Carlo ^a   Biglia, Nicoletta ^b   Sismondi, Piero ^b  

^a Sant'Anna Gynecological Hospital   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; HUMAN; NOTE; RISK;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTINS; RISK;

EID: 0030591217     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.275.15.1159     Document Type: Letter

References (5)

1. Stanford JL, Weiss NS, Voight LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
2. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol. 1993;7:251-258.
3. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol. 1995;9:67-74.
4. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87:190-197.
5. Campagnoli C, Biglia N, Lanza MG, et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women: preliminary report. Maturitas. 1994;19:25-31.